物质使用障碍人群中BNT162b2与CoronaVac对奥密克戎感染及住院的疫苗有效性
本研究基于香港电子健康数据库,采用匹配病例对照设计,评估物质使用障碍人群中BNT162b2和CoronaVac对SARS-CoV-2奥密克戎感染及相关住院的疫苗有效性。结果显示,两剂或三剂接种对COVID-19相关住院有保护作用,加强针对感染也有保护作用,但单剂或两剂CoronaVac对感染无显著保护。
要点
- 两剂或三剂BNT162b2或CoronaVac对物质使用障碍人群的COVID-19相关住院有显著保护。
- 三剂BNT162b2或CoronaVac及异源加强对SARS-CoV-2感染有显著保护。
- 单剂任一疫苗或两剂CoronaVac对感染无显著保护,单剂CoronaVac对住院无显著保护。
核心结论
- 在物质使用障碍人群中,两剂或三剂接种BNT162b2或CoronaVac对COVID-19相关住院有保护作用,加强针对SARS-CoV-2感染也有保护作用。
研究设计与样本
- 采用香港电子健康数据库的匹配病例对照研究,纳入2016年1月1日至2022年1月1日诊断为物质使用障碍的18岁及以上个体。
- 感染病例为2022年1月1日至5月31日SARS-CoV-2感染者,住院病例为2022年2月16日至5月31日COVID-19相关住院者,按年龄、性别和既往临床史匹配对照。
- 感染分析匹配最多3名对照,住院分析匹配最多10名对照,使用条件逻辑回归评估接种状态与结局的关联,调整基线合并症和用药。
临床怎么用
- 对物质使用障碍人群,应优先完成两剂或三剂COVID-19疫苗接种以降低住院风险。
- 在奥密克戎变异株流行期间,加强针接种对预防SARS-CoV-2感染具有保护作用。
- 单剂CoronaVac对住院无显著保护,应避免仅接种单剂CoronaVac。
局限性
- 数据中未获取种族信息。
- 研究为观察性设计,可能存在未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with substance use disorder have a high risk of SARS-CoV-2 infection and subsequent poor outcomes. Few studies have evaluated COVID-19 vaccine effectiveness among people with substance use disorder. We aimed to estimate the vaccine effectiveness of BNT162b2 (Fosun-BioNTech) and CoronaVac (Sinovac) against SARS-CoV-2 omicron (B.1.1.529) infection and related hospital admission in this population. METHODS: We did a matched case-control study using electronic health databases in Hong Kong. Individuals diagnosed with substance use disorder between Jan 1, 2016, and Jan 1, 2022, were identified. People aged 18 years and older with SARS-CoV-2 infection from Jan 1 to May 31, 2022, and people with COVID-19-related hospital admission from Feb 16 to May 31, 2022, were included as cases and were matched by age, sex, and previous clinical history with controls from all individuals diagnosed with substance use disorder who attended the Hospital Authority health services: up to three controls for SARS-CoV-2 infection and up to ten controls for hospital admission. Conditional logistical regression was used to evaluate the association between vaccination status (ie, one, two, or three doses of BNT162b2 or CoronaVac) and the risk of SARS-CoV-2 infection and COVID-19-related hospital admission, adjusted for baseline comorbidities and medication use. FINDINGS: Among 57 674 individuals with substance use disorder, 9523 people with SARS-CoV-2 infections (mean age 61·00 years, SD 14·90; 8075 [84·8%] males and 1448 [15·2%] females) were identified and matched to 28 217 controls (mean age 60·99 years, 14·67; 24 006 [85·1%] males and 4211 [14·9%] females), and 843 people with COVID-19-related hospital admissions (mean age 70·48 years, SD 14·68; 754 [89·4%] males and 89 [10·6%] females) were identified and matched to 7459 controls (mean age 70·24 years, 13·87; 6837 [91·7%] males and 622 [8·3%] females). Data on ethnicity were not available. We observed significant vaccine effectiveness against SARS-CoV-2 infection for two-dose BNT162b2 vaccination (20·7%, 95% CI 14·0-27·0, p<0·0001) and three-dose vaccination (all BNT162b2 41·5%, 34·4-47·8, p<0·0001; all CoronaVac 13·6%, 5·4-21·0, p=0·0015; BNT162b2 booster after two-dose CoronaVac 31·3%, 19·8-41·1, p<0·0001), but not for one dose of either vaccine or two doses of CoronaVac. Significant vaccine effectiveness against COVID-19-related hospital admission was detected after one dose of BNT162b2 vaccination (35·7%, 3·8-57·1, p=0·032), two-dose vaccination (both BNT162b2 73·3%, 64·3 to 80·0, p<0·0001; both CoronaVac 59·9%, 50·2-67·7, p<0·0001), and three-dose vaccination (all BNT162b2 86·3%, 75·6-92·3, p<0·0001; all CoronaVac 73·5% 61·0-81·9, p<0·0001; BNT162b2 booster after two-dose CoronaVac 83·7%, 64·6-92·5, p<0·0001), but not after one dose of CoronaVac. INTERPRETATION: For both BNT162b2 and CoronaVac, two-dose or three-dose vaccination was protective against COVID-19-related hospital admission and the booster dose provided protection against SARS-CoV-2 infection among people with substance use disorder. Our findings confirm the importance of booster doses in this population during the period dominated by the omicron variant. FUNDING: Health Bureau, the Government of the Hong Kong Special Administrative Region.
引用
- Huang C, Wei Y, Yan VKC, et al. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study. Lancet Psychiatry. 2023. PMID: 37141907. doi:10.1016/S2215-0366(23)00111-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。